OmniRayn
← All repurposing reports
S2 (505(b)(2))

Retinoblastoma

Known, approved drugs ranked as repurposing candidates for Retinoblastoma — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1dasatinibApproved
  2. 2estradiolApproved
  3. 3toremifeneApproved
  4. 4selumetinibApproved
  5. 5testosteroneApproved
  6. 6flucytosineApproved
  7. 7palbociclibApproved
  8. 85 aminolevulinic acidApproved

Full dossier — 143 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950